Immunology Fall 2026: Lecture 24 T cell Activation and Effector Function
Overview
Brianne Barker explains how naive T cells require antigen recognition, CD28 co-stimulation, and cytokine signals such as IL-2 to activate safely, then differentiate into effector cells. The lecture connects dendritic-cell PRR sensing to B7 expression, describes inhibitory checkpoints CTLA-4 and PD-1, and shows how CD8 cytotoxic T cells kill targets through Fas ligand or perforin and granzyme B.
Key takeaways
- Naive T cells require both T-cell receptor recognition and CD28 binding to B7, which is also called CD80 or CD86; recognizing peptide-MHC without co-stimulation can induce anergy.
- Dendritic-cell PRR detection of microbial patterns promotes B7 expression, providing a mechanistic link between innate danger sensing and adaptive T-cell activation.
- IL-2 signals through the JAK-STAT pathway, and activation-induced CD25 combines with IL-2 receptor beta and gamma chains to create a high-affinity receptor that supports T-cell survival and division.
- CTLA-4 competes with CD28 for B7 and binds it more strongly, while PD-1 is associated with inhibitory signaling and can increase during prolonged antigen exposure and T-cell exhaustion.
- A CD8 T cell becomes a CTL only after activation and differentiation; it can then kill multiple antigen-bearing cells while sparing nearby uninfected tissue.
- CTLs induce target-cell apoptosis through Fas ligand binding Fas or by releasing perforin and granzyme B directionally at the immunologic synapse; granzyme B can directly activate caspase 3.
Chapters
- The Thursday review session will be held at 7:00 on Google Meet, and a paper related to co-stimulation and CD8 T cells is planned for Wednesday discussion.
- Naive T-cell activation involves signal 1 through the T-cell receptor and co-receptor, signal 2 through co-stimulation, and cytokine signals sometimes called signal 3.
- IL-2 is important for T cells broadly, while additional cytokines will be considered when the course turns to CD4 T cells.
- Cytokine binding brings receptor chains together, allowing associated JAK kinases to phosphorylate one another and create binding sites for STAT proteins.
- JAKs phosphorylate STATs, which pair up and act as transcription factors; different cytokines use different JAK and STAT family members.
- Naive T cells have IL-2 receptor beta and gamma chains, while activation induces the alpha chain, CD25, to form a high-affinity receptor.
- IL-2 made by an activating T cell can act on that cell or a nearby T cell to support survival and division; JAK inhibitors reduce cytokine signaling and are used in some autoimmune diseases.
- CD28 on a naive T cell binds B7-1 and B7-2, also called CD80 and CD86, on an antigen-presenting cell to deliver signal 2.
- Because thymic selection leaves T cells with some low-level self-reactivity, signal 2 provides an additional safeguard against inappropriate activation.
- Dendritic cells increase B7 after activation, so antigen recognition without a danger-associated co-stimulatory signal is less likely to activate a naive T cell.
- Dendritic-cell PRRs detect microbial patterns such as MAMPs or PAMPs and promote B7 expression, linking innate sensing to adaptive T-cell activation.
- A T cell that recognizes peptide-MHC without CD28-B7 co-stimulation becomes anergic, a state that helps prevent responses to self antigens.
- In laboratory experiments, T cells need both a signal through CD3, such as an anti-CD3 stimulus, and a CD28 stimulus for robust activation.
- Once a T cell has been activated, it can respond to antigen with less dependence on signal 2, allowing effector cells to act in peripheral tissues.
- CD28 is the best-known activating co-stimulatory receptor, but T cells also use inhibitory receptors that reduce activation.
- Activated T cells need mechanisms to turn them off after infection control, because continued activity can lead to damage or attacks on healthy tissue.
- The need for control changes after activation: naive T cells require strong co-stimulation, whereas effector T cells are less dependent on it.
- After activation, T cells begin expressing CTLA-4, which binds the same B7 ligands as CD28.
- CTLA-4 binds B7 more strongly than CD28, limiting the activating interaction and delivering an inhibitory signal.
- Inducing CTLA-4 alongside the high-affinity IL-2 receptor helps build a shutdown mechanism into the developing T-cell response.
- PD-1 is an inhibitory receptor associated with activated T cells; prolonged antigen stimulation can drive high PD-1 expression and a dysfunctional exhausted state.
- T-cell exhaustion can impair responses to chronic infections and tumors, where immune cells may encounter antigen for extended periods.
- Checkpoint inhibitor therapies block inhibitory pathways such as PD-1 or CTLA-4 to restore antitumor T-cell activity; examples discussed include Opdivo and Keytruda, whose generic name is pembrolizumab.
- Removing inhibitory signals can help tumor-targeting T cells but also makes it harder to restrain immune responses.
- Following activation, T cells proliferate, leave lymphoid organs, and differentiate into effector cells with new functions.
- Naive T cells use molecules such as L-selectin and CCR7 to travel between blood and lymph nodes; activated cells alter their trafficking program to reach infected peripheral tissues.
- A CD8 T cell differentiates into a cytotoxic T lymphocyte, or CTL, while a CD4 T cell becomes a helper cell.
- After activation and differentiation, a CTL recognizes antigen on a target cell and kills it with specificity, sparing neighboring uninfected tissue cells.
- CTL killing occurs in peripheral tissues after the cell has acquired effector function, not during its initial activating contact with a dendritic cell.
- A single CTL can kill multiple infected cells in succession rather than requiring one CTL for every target.
- Injected mRNA enters the cytoplasm, where cells translate it into antigen that can be presented on MHC class I.
- Dendritic cells can present vaccine antigen in lymph nodes to activate naive T cells, but the initial interaction does not make the dendritic cells targets for killing.
- CTL killing is a later effector function: the activated CD8 cell must differentiate before it can kill antigen-bearing cells.
- Activated CTLs express Fas ligand, which binds Fas on a target cell and induces apoptosis.
- The Fas pathway proceeds through multiple signaling steps, including mitochondrial involvement, before activating executioner caspase 3.
- Apoptosis packages and dismantles the target cell, unlike uncontrolled cell rupture associated with necrosis.
- Activated CTLs form lytic, or cytotoxic, granules containing proteins that can kill target cells.
- At the immunologic synapse, integrins help hold the CTL and target together while granules are directed into the contact zone.
- Directional secretion concentrates toxic granule contents on the antigen-bearing target instead of dispersing them throughout nearby tissue.
- Perforin assembles into membrane pores in the target cell; its pores resemble those formed by the complement membrane attack complex.
- Perforin also enables granzyme B to enter the target cell, where granzyme B can directly activate caspase 3 and accelerate apoptosis.
- CTLs also produce interferon gamma, another contribution to the immune response.
- The CD8 response proceeds from lymph-node activation with signal 1, signal 2, and IL-2 through proliferation and differentiation into CTLs.
- CTLs then traffic to peripheral tissue and kill infected cells using Fas ligand or cytotoxic granules containing perforin and granzymes.
- CD4 T-cell effector function is scheduled as the next major topic after the exam; suggested review songs include Ode to Ben and Jen and Cyclosporin Blues.
Transcript excerpt
0:00 All right. Hi everybody. I hope that you are all doing well. Um, some general stuff uh before I get started. Um, so based on the um responses to the poll um the resession will be on um Thursday at 7:00. Um, and so uh I sent you an email with the link in it and I also sent you a calendar invite which also has the link in it um so that you have that information. Um, it'll be on Google Meet so you have that that link. Um, so all of that is uh available. Um, and
0:48 um the other thing I wanted to make sure to remind you is I've told you a couple times about the um Boston University Select Scholars program um info session. That info session is tomorrow. Um, and so if that's something that you're interested in um you can get take a look at the info on that slide um that's on Moodle um about that info session that is tomorrow. Um, otherwise um I have a paper pulled up on my laptop for us to talk about on Wednesday, but I need to write questions. [laughter] So let me so uh I need to send so I'll send you that paper and then I'll get some questions written. Um, I I'm going to tell you they're probably not going to be the world's most in-depth questions. Um,
1:36 but um and and the details of the paper are going to be very much related to some of the stuff we're talking about today. Um, and otherwise um as always let me know if you have questions or other things that you want to talk about. Um, so today we're going to um finish talking about um some really important details T-cell activation. I actually
This is the start of the transcript. Save this video free for the whole transcript, searchable and time-coded.
In this course
Related notes
Summary, takeaways, and chapters were generated by AI from the video's transcript and may contain errors. The video belongs to its creator, Brianne Barker.